Medullary Thyroid Cancer: Monitoring and Therapy

Research output: Contribution to journalArticle

Abstract

This article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.

Original languageEnglish (US)
Pages (from-to)823-837
Number of pages15
JournalEndocrinology and Metabolism Clinics of North America
Volume36
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Monitoring
Vascular Endothelial Growth Factor Receptor
Molecular Imaging
Residual Neoplasm
Therapeutics
Thyroid Neoplasms
Surgery
Clinical Trials
Imaging techniques
Molecules
Medullary Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry

Cite this

Medullary Thyroid Cancer : Monitoring and Therapy. / Ball, Douglas W.

In: Endocrinology and Metabolism Clinics of North America, Vol. 36, No. 3, 09.2007, p. 823-837.

Research output: Contribution to journalArticle

@article{3e5a12efe8b24c85b5745bce7e39f05a,
title = "Medullary Thyroid Cancer: Monitoring and Therapy",
abstract = "This article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.",
author = "Ball, {Douglas W}",
year = "2007",
month = "9",
doi = "10.1016/j.ecl.2007.04.001",
language = "English (US)",
volume = "36",
pages = "823--837",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Medullary Thyroid Cancer

T2 - Monitoring and Therapy

AU - Ball, Douglas W

PY - 2007/9

Y1 - 2007/9

N2 - This article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.

AB - This article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.

UR - http://www.scopus.com/inward/record.url?scp=34547191205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547191205&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2007.04.001

DO - 10.1016/j.ecl.2007.04.001

M3 - Article

C2 - 17673130

AN - SCOPUS:34547191205

VL - 36

SP - 823

EP - 837

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 3

ER -